923469577	923469577	CD	B-NP	O
|	|	NN	I-NP	O
RTCH	RTCH	NN	I-NP	O
|	|	NN	I-NP	O
84878000	84878000	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
0383124	0383124	CD	B-NP	O
|	|	CC	I-NP	O
10/27/2004	10/27/2004	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Summary	Summary	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/29/2004	10/29/2004	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/22/2004	10/22/2004	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
KIP	KIP	NNP	B-NP	O
ABRAM	ABRAM	NNP	I-NP	O
SKOKOWSKI	SKOKOWSKI	NNP	I-NP	O
MD	MD	NNP	I-NP	O
PRINCIPAL	PRINCIPAL	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
Chemotherapy	Chemotherapy	NN	B-NP	O
toxicity	toxicity	NN	I-NP	O
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
dehydration	dehydration	NN	B-NP	O
,	,	,	O	O
colitis	colitis	NN	B-NP	O
,	,	,	O	O
liver	liver	NN	B-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

ASSOCIATED	ASSOCIATED	VBN	B-NP	O
PROBLEMS/DIAGNOSES	PROBLEMS/DIAGNOSES	NNPS	I-NP	O
:	:	:	O	O
Hypotension	Hypotension	NN	B-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
esophagitis	esophagitis	NN	B-NP	O
,	,	,	O	O
congestive	congestive	JJ	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

HISTORY	HISTORY	NN	B-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	JJ	B-NP	O
ILLNESS	ILLNESS	NN	I-NP	O
:	:	:	O	O
Ms.	Ms.	NNP	B-NP	O
Linsenmayer	Linsenmayer	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
68-year-old	68-year-old	JJ	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
metastatic	metastatic	JJ	B-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
that	that	WDT	B-NP	O
was	be	VBD	B-VP	O
first	first	RB	I-VP	O
diagnosed	diagnose	VBN	I-VP	O
in	in	IN	B-PP	O
1999	1999	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
lumpectomy	lumpectomy	NN	I-NP	O
with	with	IN	B-PP	O
lymph	lymph	NN	B-NP	O
node	node	NN	I-NP	O
dissection	dissection	NN	I-NP	O
and	and	CC	O	O
multiple	multiple	JJ	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
regimens	regimen	NNS	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
on	on	IN	B-PP	O
Xeloda	Xeloda	NNP	B-NP	O
with	with	IN	B-PP	O
excellent	excellent	JJ	B-NP	O
response	response	NN	I-NP	O
;	;	:	O	O
per	per	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Cagan	Cagan	NNP	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
oncologist	oncologist	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
virtually	virtually	RB	B-NP	O
no	no	DT	I-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
metastatic	metastatic	JJ	B-NP	O
disease	disease	NN	I-NP	O
on	on	IN	B-PP	O
CT.	CT.	NNP	B-NP	O
.	.	.	O	O

Over	Over	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
few	few	JJ	I-NP	O
months	month	NNS	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
chronic	chronic	JJ	B-NP	O
problems	problem	NNS	I-NP	O
with	with	IN	B-PP	O
nausea	nausea	NN	B-NP	O
and	and	CC	O	O
decreased	decrease	VBN	B-NP	O
appetite	appetite	NN	I-NP	O
.	.	.	O	O

This	This	DT	B-NP	O
has	have	VBZ	B-VP	O
become	become	VBN	I-VP	O
especially	especially	RB	B-ADJP	O
acute	acute	JJ	I-ADJP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
week	week	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
as	as	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
is	be	VBZ	B-VP	O
now	now	RB	B-ADVP	O
on	on	IN	B-PP	O
hold	hold	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
also	also	RB	I-VP	O
had	have	VBD	I-VP	O
some	some	DT	B-NP	O
worsening	worsen	VBG	I-NP	O
diarrhea	diarrhea	NN	I-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
prescribed	prescribe	VBN	I-VP	O
Imodium	Imodium	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
because	because	IN	B-PP	O
of	of	IN	I-PP	O
ongoing	ongoing	JJ	B-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
compliance	compliance	NN	B-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
taking	take	VBG	I-VP	O
enough	enough	RB	B-ADVP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
.	.	.	O	O

During	During	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
visit	visit	NN	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
90/50	90/50	CD	B-NP	O
,	,	,	O	O
so	so	RB	O	O
her	her	PRP$	B-NP	O
dose	dose	NN	I-NP	O
of	of	IN	B-PP	O
atenolol	atenolol	NN	B-NP	O
and	and	CC	I-NP	O
Lasix	Lasix	NN	I-NP	O
was	be	VBD	B-VP	O
decreased	decrease	VBN	I-VP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
status	status	NN	B-NP	O
post	post	IN	B-PP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
admission	admission	NN	I-NP	O
to	to	TO	B-PP	O
MH	MH	NN	B-NP	O
for	for	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
toxicity	toxicity	NN	I-NP	O
,	,	,	O	O
so	so	RB	O	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
is	be	VBZ	B-VP	O
now	now	RB	B-ADVP	O
also	also	RB	B-ADVP	O
on	on	IN	B-PP	O
hold	hold	NN	B-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
currently	currently	RB	B-ADVP	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
despite	despite	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
due	due	JJ	B-PP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
GI	GI	NN	B-NP	O
bleeding	bleeding	NN	I-NP	O
,	,	,	O	O
possible	possible	JJ	B-NP	O
interactions	interaction	NNS	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
regimen	regimen	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
ongoing	ongoing	JJ	B-NP	O
issues	issue	NNS	I-NP	O
with	with	IN	B-PP	O
medication	medication	NN	B-NP	O
compliance	compliance	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
rehydration	rehydration	NN	B-NP	O
,	,	,	O	O
management	management	NN	B-NP	O
of	of	IN	B-PP	O
nausea/vomiting/diarrhea	nausea/vomiting/diarrhea	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
control	control	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	O
and	and	CC	O	O
other	other	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

REVIEW	REVIEW	NNP	B-NP	O
OF	OF	IN	B-PP	O
SYSTEMS	SYSTEMS	NNP	B-NP	O
:	:	:	O	O
Nausea/vomiting	Nausea/vomite	VBG	B-VP	O
x	x	NN	B-NP	O
several	several	JJ	I-NP	O
months	month	NNS	I-NP	O
,	,	,	O	O
diarrhea	diarrhea	NN	B-NP	O
approximately	approximately	RB	B-NP	O
six	six	CD	I-NP	O
times	time	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
,	,	,	O	O
worsening	worsen	VBG	B-VP	O
over	over	IN	B-PP	O
the	the	DT	B-NP	O
past	past	JJ	I-NP	O
week	week	NN	I-NP	O
with	with	IN	B-PP	O
green	green	JJ	B-NP	O
liquid	liquid	NN	I-NP	O
stool	stool	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
blood	blood	NN	I-NP	O
in	in	IN	B-PP	O
stool	stool	NN	B-NP	O
or	or	CC	I-NP	O
vomit	vomit	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
abdominal	abdominal	JJ	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
urinary	urinary	JJ	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Metastatic	Metastatic	JJ	B-NP	O
breast	breast	NN	I-NP	O
cancer	cancer	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
diagnosed	diagnose	VBN	B-VP	O
in	in	IN	B-PP	O
1999	1999	CD	B-NP	O
,	,	,	O	O
status	status	NN	B-NP	O
post	post	NN	I-NP	O
lumpectomy	lumpectomy	NN	I-NP	O
and	and	CC	O	O
lymph	lymph	NN	B-NP	O
node	node	NN	I-NP	O
dissection	dissection	NN	I-NP	O
,	,	,	O	O
formerly	formerly	RB	B-ADVP	O
on	on	IN	B-PP	O
numerous	numerous	JJ	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
regimens	regimen	NNS	I-NP	O
including	include	VBG	B-PP	O
Adriamycin/cytoxan	Adriamycin/cytoxan	NN	B-NP	O
,	,	,	O	O
Taxol	Taxol	NN	B-NP	O
,	,	,	O	O
Taxotere/Herceptin	Taxotere/Herceptin	NN	B-NP	B-protein
,	,	,	O	O
gemcitabine	gemcitabine	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation/supraventricular	fibrillation/supraventricular	JJ	I-NP	O
tachycardia	tachycardia	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
cholecystitis	cholecystitis	NN	B-NP	O
,	,	,	O	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
esophagitis	esophagitis	NN	B-NP	O
.	.	.	O	O

ADMISSION	ADMISSION	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Lasix	Lasix	NN	B-NP	O
20	20	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
aspirin	aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Xeloda	Xeloda	NNP	B-NP	O
1500	1500	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
-LRB-	-LRB-	SYM	O	O
two	two	CD	B-NP	O
weeks/one	weeks/one	NN	I-NP	O
week	week	NN	I-NP	O
off	off	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-protein
,	,	,	O	O
Zofran	Zofran	NN	B-NP	B-protein
8	8	CD	I-NP	I-protein
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
p.r.n.	p.r.n.	NN	B-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
Compazine	Compazine	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
atenolol	atenolol	NN	B-NP	O
75	75	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Lomotil	Lomotil	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
trazodone	trazodone	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
q.h.s.	q.h.s.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
insomnia	insomnia	NNP	I-NP	O
,	,	,	O	O
Percocet	Percocet	NNP	B-NP	O
325/5	325/5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
Ativan	Ativan	NNP	B-NP	O
1	1	CD	I-NP	O
mg	mg	NN	I-NP	O
q.i.d.	q.i.d.	NN	I-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
anxiety	anxiety	NN	I-NP	O
,	,	,	O	O
metformin	metformin	NN	B-NP	O
850	850	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
Vioxx	Vioxx	NNP	B-NP	O
12.5	12.5	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
ALLERGIES	ALLERGIES	NNS	I-NP	O
:	:	:	O	O
Penicillin	Penicillin	NNP	B-NP	O
.	.	.	O	O

FAMILY	FAMILY	NN	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
several	several	JJ	B-NP	O
uncles	uncle	NNS	I-NP	O
and	and	CC	I-NP	O
cousins	cousin	NNS	I-NP	O
with	with	IN	B-PP	O
cancer	cancer	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
unsure	unsure	JJ	B-ADJP	O
of	of	IN	B-PP	O
what	what	WP	B-NP	O
type	type	NN	I-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	JJ	B-NP	O
HISTORY	HISTORY	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
lives	live	VBZ	B-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
daughter	daughter	NN	I-NP	O
and	and	CC	I-NP	O
grandson	grandson	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
no	no	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
tobacco	tobacco	NN	B-NP	O
or	or	CC	I-NP	O
alcohol	alcohol	NN	I-NP	O
use	use	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	JJ	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
:	:	:	O	O
Vital	Vital	JJ	B-NP	O
signs	sign	NNS	I-NP	O
:	:	:	O	O
Temperature	Temperature	NN	B-NP	B-protein
97.9	97.9	CD	I-NP	I-protein
,	,	,	O	O
pulse	pulse	NN	B-NP	O
101	101	CD	I-NP	O
,	,	,	O	O
BP	BP	NN	B-NP	B-protein
80/66	80/66	CD	I-NP	I-protein
,	,	,	O	O
respiratory	respiratory	JJ	B-NP	O
rate	rate	NN	I-NP	O
16	16	CD	I-NP	O
,	,	,	O	O
O2	O2	NN	B-NP	O
sat	sit	VBD	B-VP	O
99	99	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

General	General	NNP	B-NP	O
:	:	:	O	O
Alert	Alert	NNP	B-NP	O
,	,	,	O	O
Spanish-speaking	Spanish-speaking	NNP	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

HEENT	HEENT	NN	B-NP	O
:	:	:	O	O
PERRL	PERRL	NN	B-NP	B-protein
,	,	,	O	O
EOMI	EOMI	NN	B-NP	B-protein
,	,	,	O	O
poor	poor	JJ	B-NP	O
dentition	dentition	NN	I-NP	O
,	,	,	O	O
OP	OP	NN	B-NP	O
clear	clear	JJ	B-ADJP	O
.	.	.	O	O

Neck	Neck	NN	B-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
LAD	LAD	NN	I-NP	B-protein
,	,	,	O	O
FROM	FROM	NN	B-NP	O
,	,	,	O	O
supple	supple	NN	B-NP	O
.	.	.	O	O

Chest	Chest	NNP	B-NP	O
:	:	:	O	O
CTAB	CTAB	NN	B-NP	B-protein
.	.	.	O	O

CV	CV	NN	B-NP	O
:	:	:	O	O
Irregularly	Irregularly	RB	B-ADJP	O
irregular	irregular	JJ	I-ADJP	O
,	,	,	O	O
S1	S1	NN	B-NP	B-protein
,	,	,	O	O
S2	S2	NN	B-NP	B-protein
,	,	,	O	O
no	no	DT	B-NP	O
murmurs/rubs/gallops	murmurs/rubs/gallop	NNS	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
:	:	:	O	O
Soft	Soft	JJ	B-NP	O
,	,	,	I-NP	O
distended	distended	JJ	I-NP	O
,	,	,	I-NP	O
mild	mild	JJ	I-NP	O
tenderness	tenderness	NN	I-NP	O
to	to	TO	B-PP	O
palpation	palpation	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
lower	low	JJR	I-NP	O
quadrants	quadrant	NNS	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
,	,	,	O	O
slightly	slightly	RB	B-NP	O
tympanitic	tympanitic	JJ	I-NP	O
,	,	,	I-NP	O
normoactive	normoactive	JJ	I-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
hepatosplenomegaly	hepatosplenomegaly	NN	I-NP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
:	:	:	O	O
Warm/well	Warm/well	NNP	B-NP	O
perfused	perfuse	VBD	B-VP	O
,	,	,	O	O
trace	trace	NN	B-NP	O
DP/PT	DP/PT	NN	I-NP	O
pulses	pulse	NNS	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
clubbing/cyanosis/edema	clubbing/cyanosis/edema	NN	I-NP	O
,	,	,	O	O
ulcer	ulcer	NN	B-NP	O
on	on	IN	B-PP	O
left	left	JJ	B-NP	O
large	large	JJ	I-NP	O
toe	toe	NN	I-NP	O
,	,	,	O	O
severely	severely	RB	B-NP	O
cracked	cracked	JJ	I-NP	O
and	and	CC	I-NP	O
dry	dry	JJ	I-NP	O
skin	skin	NN	I-NP	O
on	on	IN	B-PP	O
hands	hand	NNS	B-NP	O
and	and	CC	I-NP	O
feet	foot	NNS	I-NP	O
.	.	.	O	O

Neuro	Neuro	NNP	B-NP	O
:	:	:	O	O
Cranial	Cranial	NNP	B-NP	O
nerves	nerve	VBZ	B-VP	O
II	II	CD	B-NP	O
through	through	IN	I-NP	O
XII	XII	CD	I-NP	B-DNA
grossly	grossly	RB	I-NP	O
intact	intact	JJ	I-NP	O
,	,	,	O	O
5/5	5/5	CD	B-NP	O
strength	strength	NN	I-NP	O
throughout	throughout	IN	B-ADVP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
VALUES	VALUES	NNS	I-NP	O
:	:	:	O	O
Significant	Significant	JJ	B-ADJP	O
for	for	IN	B-PP	O
creatinine	creatinine	NN	B-NP	B-protein
1.3	1.3	CD	I-NP	I-protein
,	,	,	O	O
glucose	glucose	NN	B-NP	O
137	137	CD	I-NP	O
,	,	,	O	O
WBC	WBC	NNP	B-NP	O
9.6	9.6	CD	I-NP	O
with	with	IN	B-PP	O
28	28	CD	B-NP	O
polys	poly	NNS	I-NP	O
and	and	CC	O	O
29	29	CD	B-NP	O
bands	band	NNS	I-NP	O
,	,	,	O	O
hematocrit	hematocrit	NN	B-NP	B-protein
38.1	38.1	CD	I-NP	I-protein
,	,	,	O	O
total	total	JJ	B-NP	O
protein	protein	NN	I-NP	O
5.2	5.2	CD	I-NP	O
,	,	,	O	O
albumin	albumin	NN	B-NP	B-protein
2.0	2.0	CD	I-NP	I-protein
,	,	,	O	O
ALT	ALT	NN	B-NP	B-DNA
41	41	CD	I-NP	I-DNA
,	,	,	O	O
AST	AST	NN	B-NP	O
18	18	CD	I-NP	O
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
61	61	CD	B-NP	O
,	,	,	O	O
total	total	JJ	B-NP	O
bilirubin	bilirubin	NN	I-NP	O
2.5	2.5	CD	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
EKG	EKG	NN	I-NP	O
showed	show	VBD	B-VP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
at	at	IN	B-PP	O
approximately	approximately	RB	B-NP	O
140	140	CD	I-NP	O
beats/minute	beats/minute	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
ST	ST	NN	I-NP	O
or	or	CC	I-NP	O
T	T	NN	I-NP	O
wave	wave	NN	I-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
Colitis	Colitis	NN	B-NP	O
:	:	:	O	O
Given	Give	VBN	B-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
persistent	persistent	JJ	I-NP	O
and	and	CC	I-NP	O
chronic	chronic	JJ	I-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
vomiting	vomiting	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
diarrhea	diarrhea	NN	B-NP	O
,	,	,	O	O
there	there	EX	B-NP	O
was	be	VBD	B-VP	O
significant	significant	JJ	B-NP	O
concern	concern	NN	I-NP	O
for	for	IN	B-PP	O
small	small	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
obstruction	obstruction	NN	I-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
a	a	DT	B-NP	O
KUB	KUB	NN	I-NP	B-protein
and	and	CC	I-NP	O
abdominal	abdominal	JJ	I-NP	O
CT	CT	NN	I-NP	O
were	be	VBD	B-VP	O
both	both	CC	O	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
small	small	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
obstruction	obstruction	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
originally	originally	RB	I-VP	O
kept	keep	VBN	I-VP	O
n.p.o.	n.p.o.	NN	B-NP	O
for	for	IN	B-PP	O
bowel	bowel	NN	B-NP	O
rest	rest	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
a	a	DT	B-NP	O
nasogastric	nasogastric	JJ	I-NP	O
tube	tube	NN	I-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
with	with	IN	B-PP	O
significant	significant	JJ	B-NP	O
drainage	drainage	NN	I-NP	O
.	.	.	O	O

Stool	Stool	NN	B-NP	O
studies	study	NNS	I-NP	O
were	be	VBD	B-VP	O
sent	send	VBN	I-VP	O
including	include	VBG	B-PP	O
C.	C.	NNP	B-NP	O
difficile	difficile	NNP	I-NP	O
,	,	,	O	O
ova	ova	NN	B-NP	O
and	and	CC	I-NP	O
parasites	parasite	NNS	I-NP	O
,	,	,	O	O
cecal	cecal	JJ	B-NP	B-cell_type
leukocytes	leukocyte	NNS	I-NP	I-cell_type
,	,	,	O	O
and	and	CC	O	O
Shigella/salmonella/Yersinia	Shigella/salmonella/Yersinia	NN	B-NP	O
/	/	SYM	O	O
campylobacter	campylobacter	NN	B-NP	O
studies	study	NNS	I-NP	O
,	,	,	O	O
all	all	DT	B-NP	O
of	of	IN	B-PP	O
which	which	WDT	B-NP	O
were	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
the	the	DT	B-NP	O
concerning	concern	VBG	I-NP	O
nature	nature	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
symptoms	symptom	NNS	I-NP	O
,	,	,	O	O
surgery	surgery	NN	B-NP	O
consult	consult	NN	I-NP	O
was	be	VBD	B-VP	O
called	call	VBN	I-VP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
they	they	PRP	B-NP	O
felt	feel	VBD	B-VP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
problems	problem	NNS	I-NP	O
were	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
nonsurgical	nonsurgical	JJ	I-ADJP	O
in	in	IN	B-PP	O
nature	nature	NN	B-NP	O
.	.	.	O	O

CTs	CT	NNS	B-NP	B-protein
performed	perform	VBD	B-VP	O
two	two	CD	B-NP	O
days	day	NNS	I-NP	O
and	and	CC	O	O
five	five	CD	B-NP	O
days	day	NNS	I-NP	O
after	after	IN	B-SBAR	O
admission	admission	NN	B-NP	O
showed	show	VBD	B-VP	O
identical	identical	JJ	B-NP	O
findings	finding	NNS	I-NP	O
of	of	IN	B-PP	O
right-sided	right-sided	JJ	B-NP	O
colitis	colitis	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
remained	remain	VBD	B-VP	O
largely	largely	RB	B-ADJP	O
unchanged	unchanged	JJ	I-ADJP	O
.	.	.	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
experienced	experience	VBD	B-VP	O
continued	continue	VBN	B-NP	O
nausea	nausea	NN	I-NP	O
and	and	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
continued	continue	VBD	B-VP	O
diarrhea	diarrhea	NN	B-NP	O
throughout	throughout	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Once	Once	RB	O	O
her	her	PRP$	B-NP	O
nasogastric	nasogastric	JJ	I-NP	O
tube	tube	NN	I-NP	O
output	output	NN	I-NP	O
decreased	decrease	VBD	B-VP	O
significantly	significantly	RB	B-ADVP	O
,	,	,	O	O
approximately	approximately	RB	B-NP	O
one	one	CD	I-NP	O
week	week	NN	I-NP	O
after	after	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
tube	tube	NN	I-NP	O
was	be	VBD	B-VP	O
removed	remove	VBN	I-VP	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
p.o.	p.o.	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
diet	diet	NN	I-NP	O
was	be	VBD	B-VP	O
advanced	advance	VBN	I-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-VP	O
.	.	.	O	O

From	From	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
on	on	IN	B-PP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
nausea	nausea	NN	I-NP	O
or	or	CC	I-NP	O
vomiting	vomiting	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	I-VP	O
tolerating	tolerate	VBG	I-VP	O
a	a	DT	B-NP	O
full	full	JJ	I-NP	O
diet	diet	NN	I-NP	O
.	.	.	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O
,	,	,	O	O
she	she	PRP	B-NP	O
continues	continue	VBZ	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
mild	mild	JJ	B-NP	O
diarrhea	diarrhea	NN	I-NP	O
,	,	,	O	O
now	now	RB	B-ADVP	O
two	two	CD	B-NP	O
episodes	episode	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
as	as	IN	B-SBAR	O
compared	compare	VBN	B-NP	O
to6	to6	CD	I-NP	O
to	to	TO	I-NP	O
8	8	CD	I-NP	O
episodes	episode	NNS	I-NP	O
per	per	IN	B-PP	O
day	day	NN	B-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
the	the	DT	B-NP	O
end	end	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
workup	workup	NN	I-NP	O
for	for	IN	B-PP	O
the	the	DT	B-NP	O
underlying	underlie	VBG	I-NP	O
cause	cause	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
nausea	nausea	NN	I-NP	O
,	,	,	O	O
vomiting	vomiting	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
diarrhea	diarrhea	NN	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
therefore	therefore	RB	B-ADVP	O
our	our	PRP$	B-NP	O
suspicion	suspicion	NN	I-NP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
are	be	VBP	B-VP	O
most	most	RBS	B-ADVP	O
likely	likely	RB	I-ADVP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
toxicity	toxicity	NN	B-NP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
medication	medication	NN	I-NP	O
,	,	,	O	O
Xeloda	Xeloda	NNP	B-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
has	have	VBZ	B-VP	O
other	other	JJ	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
Xeloda	Xeloda	NNP	B-NP	O
toxicity	toxicity	NN	I-NP	O
,	,	,	O	O
including	include	VBG	B-PP	O
possible	possible	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
see	see	VBP	B-VP	O
below	below	IN	B-PP	O
-RRB-	-RRB-	NN	B-NP	B-protein
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
severe	severe	JJ	B-NP	O
cracking	cracking	NN	I-NP	O
and	and	CC	I-NP	O
drying	drying	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
skin	skin	NN	I-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
hands	hand	NNS	I-NP	O
and	and	CC	I-NP	O
feet	foot	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Hepatitis	Hepatitis	NN	B-NP	O
:	:	:	O	O
A	A	DT	B-NP	O
CT	CT	NN	I-NP	O
performed	perform	VBN	B-VP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
to	to	TO	B-VP	O
evaluate	evaluate	VB	I-VP	O
for	for	IN	B-PP	O
small	small	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
obstruction	obstruction	NN	I-NP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
significantly	significantly	RB	I-NP	O
cirrhotic	cirrhotic	JJ	I-NP	O
and	and	CC	I-NP	O
fatty	fatty	JJ	I-NP	O
liver	liver	NN	I-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
masses	mass	NNS	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
total	total	JJ	I-NP	O
bilirubin	bilirubin	NN	I-NP	O
was	be	VBD	B-VP	O
2.5	2.5	CD	B-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
bilirubin	bilirubin	NN	I-NP	O
levels	level	NNS	I-NP	O
escalated	escalate	VBN	B-VP	O
precipitously	precipitously	RB	B-ADVP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
maximum	maximum	NN	I-NP	O
of	of	IN	B-PP	O
17.6	17.6	CD	B-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
clinical	clinical	JJ	B-NP	O
manifestations	manifestation	NNS	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
,	,	,	O	O
including	include	VBG	B-PP	O
scleral	scleral	JJ	B-NP	O
icterus	icterus	NN	I-NP	O
and	and	CC	I-NP	O
jaundice	jaundice	NN	I-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
,	,	,	O	O
as	as	IN	B-PP	O
her	her	PRP$	B-NP	O
albumin	albumin	NN	I-NP	O
levels	level	NNS	I-NP	O
decreased	decrease	VBD	B-VP	O
to	to	TO	B-PP	O
below	below	IN	B-PP	O
1.5	1.5	CD	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
significant	significant	JJ	B-NP	O
ascites	ascite	NNS	I-NP	O
and	and	CC	O	O
peripheral	peripheral	JJ	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

Gastroenterology	Gastroenterology	NN	B-NP	O
consult	consult	NN	I-NP	O
suggested	suggest	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
quadrant	quadrant	JJ	I-NP	O
ultrasound	ultrasound	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
obstruction	obstruction	NN	B-NP	O
,	,	,	O	O
a	a	DT	B-NP	O
hepatic	hepatic	JJ	I-NP	B-protein
MRI	MRI	NN	I-NP	I-protein
,	,	,	O	O
which	which	WDT	B-NP	O
also	also	RB	B-ADVP	O
showed	show	VBD	B-VP	O
a	a	DT	B-NP	O
cirrhotic	cirrhotic	JJ	I-NP	O
and	and	CC	I-NP	O
fatty	fatty	JJ	I-NP	O
liver	liver	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
a	a	DT	B-NP	O
diagnostic/therapeutic	diagnostic/therapeutic	JJ	I-NP	O
IR	IR	NN	I-NP	O
guided	guide	VBD	B-VP	O
paracentesis	paracentesis	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
drained	drain	VBD	B-VP	O
1	1	CD	B-NP	O
liter	liter	NN	I-NP	O
of	of	IN	B-PP	O
sterile	sterile	JJ	B-NP	O
fluid	fluid	NN	I-NP	O
.	.	.	O	O

Hepatitis	Hepatitis	NN	B-NP	O
serologies	serology	NNS	I-NP	O
were	be	VBD	B-VP	O
also	also	RB	I-VP	O
sent	send	VBN	I-VP	O
,	,	,	O	O
and	and	CC	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
hepatitis	hepatitis	NN	B-NP	O
A	A	NN	I-NP	O
and	and	CC	I-NP	O
B	B	NN	I-NP	O
negative	negative	JJ	B-ADJP	O
,	,	,	O	O
but	but	CC	O	O
C	C	NN	B-ADJP	O
positive	positive	JJ	I-ADJP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
viral	viral	JJ	I-NP	O
load	load	NN	I-NP	O
was	be	VBD	B-VP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
assay	assay	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
AFP	AFP	NN	I-NP	O
was	be	VBD	B-VP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
rheumatologic	rheumatologic	JJ	I-NP	O
workup	workup	NN	I-NP	O
for	for	IN	B-PP	O
autoimmune	autoimmune	JJ	B-NP	O
hepatitis	hepatitis	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
negative	negative	JJ	B-ADJP	O
.	.	.	O	O

Because	Because	IN	B-PP	O
of	of	IN	I-PP	O
the	the	DT	B-NP	O
acuteness	acuteness	NN	I-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
timing	timing	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
presentation	presentation	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
felt	feel	VBN	I-VP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
liver	liver	NN	I-NP	O
failure	failure	NN	I-NP	O
was	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
combination	combination	NN	I-NP	O
of	of	IN	B-PP	O
hepatitis	hepatitis	NN	B-NP	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
toxicity	toxicity	NN	B-NP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
Xeloda	Xeloda	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
hepatic	hepatic	JJ	I-NP	O
function	function	NN	I-NP	O
had	have	VBD	B-VP	O
been	be	VBN	I-VP	O
improving	improve	VBG	I-VP	O
significantly	significantly	RB	B-ADVP	O
for	for	IN	B-PP	O
three	three	CD	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
albumin	albumin	NN	I-NP	O
increasing	increase	VBG	B-VP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
decreasing	decrease	VBG	B-VP	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
bilirubin	bilirubin	NN	I-NP	O
levels	level	NNS	I-NP	O
also	also	RB	B-ADVP	O
decreasing	decrease	VBG	B-VP	O
.	.	.	O	O

On	On	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
total	total	JJ	I-NP	O
bilirubin	bilirubin	NN	I-NP	O
was	be	VBD	B-VP	O
16.0	16.0	CD	B-NP	O
down	down	IN	B-ADVP	O
from	from	IN	B-PP	O
17.6	17.6	CD	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
albumin	albumin	NN	I-NP	O
was	be	VBD	B-VP	O
1.9	1.9	CD	B-NP	O
up	up	RB	B-ADVP	O
from	from	IN	B-PP	O
1.5	1.5	CD	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
1.6	1.6	CD	B-NP	O
down	down	IN	B-ADVP	O
from	from	IN	B-PP	O
2.6	2.6	CD	B-NP	O
.	.	.	O	O

It	It	PRP	B-NP	O
is	be	VBZ	B-VP	O
anticipated	anticipate	VBN	I-VP	O
that	that	IN	B-SBAR	O
as	as	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
nutritional	nutritional	JJ	I-NP	O
status	status	NN	I-NP	O
continues	continue	VBZ	B-VP	O
to	to	TO	I-VP	O
improve	improve	VB	I-VP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
hepatic	hepatic	JJ	I-NP	O
function	function	NN	I-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
to	to	TO	I-VP	O
normalize	normalize	VB	I-VP	O
with	with	IN	B-PP	O
resulting	result	VBG	B-VP	O
normalization	normalization	NN	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
laboratory	laboratory	NN	I-NP	O
values	value	NNS	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
approximately	approximately	RB	B-NP	O
140	140	CD	I-NP	O
beats	beat	NNS	I-NP	O
per	per	IN	B-PP	O
minute	minute	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
hypotensive	hypotensive	JJ	B-ADJP	O
,	,	,	O	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
of	of	IN	B-PP	O
roughly	roughly	RB	B-NP	O
90/60	90/60	CD	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
on	on	IN	B-PP	O
cardiac	cardiac	JJ	B-NP	O
telemetry	telemetry	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
recorded	record	VBD	B-VP	O
rapid	rapid	JJ	B-NP	O
a.	a.	NN	I-NP	O
fib	fib	NN	I-NP	O
.	.	.	O	O

up	up	IN	B-PP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
170s	170	NNS	I-NP	B-DNA
.	.	.	O	O

As	As	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
IV	IV	CD	B-NP	O
Lopressor	Lopressor	NN	I-NP	O
with	with	IN	B-PP	O
decreased	decrease	VBN	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
but	but	CC	B-CONJP	O
also	also	RB	I-CONJP	O
significant	significant	JJ	B-NP	O
reduction	reduction	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
requiring	require	VBG	B-VP	O
fluid	fluid	NN	B-NP	O
boluses	bolus	NNS	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
24	24	CD	B-NP	O
hours	hour	NNS	I-NP	O
,	,	,	O	O
after	after	IN	B-PP	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
had	have	VBD	B-VP	O
stabilized	stabilize	VBN	I-VP	O
following	follow	VBG	B-PP	O
the	the	DT	B-NP	O
administration	administration	NN	I-NP	O
of	of	IN	B-PP	O
intravenous	intravenous	JJ	B-NP	O
fluids	fluid	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
diltiazem	diltiazem	NN	I-NP	O
drip	drip	NN	I-NP	O
at	at	IN	B-PP	O
5	5	CD	B-NP	O
mg	mg	NN	I-NP	O
per	per	IN	B-PP	O
hour	hour	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
helped	help	VBD	B-VP	O
to	to	TO	I-VP	O
establish	establish	VB	I-VP	O
stable	stable	JJ	B-NP	O
rate	rate	NN	I-NP	O
control	control	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
80s	80	NNS	I-NP	O
with	with	IN	B-PP	O
continued	continue	VBN	B-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
the	the	DT	B-NP	O
same	same	JJ	I-NP	O
time	time	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
loaded	load	VBN	I-VP	O
with	with	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
her	her	PRP$	B-NP	O
levels	level	NNS	I-NP	O
were	be	VBD	B-VP	O
high	high	JJ	B-ADJP	O
;	;	:	O	O
given	give	VBN	B-PP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
status	status	NN	B-NP	O
post	post	IN	B-PP	O
a	a	DT	B-NP	O
recent	recent	JJ	I-NP	O
admission	admission	NN	I-NP	O
for	for	IN	B-PP	O
digoxin	digoxin	NN	B-NP	O
toxicity	toxicity	NN	I-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
held	hold	VBN	I-VP	O
.	.	.	O	O

In	In	IN	B-PP	O
one	one	CD	B-NP	O
incident	incident	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
temporary	temporary	JJ	I-NP	O
junctional	junctional	JJ	I-NP	O
rhythm	rhythm	NN	I-NP	O
for	for	IN	B-PP	O
approximately	approximately	RB	B-NP	O
5	5	CD	I-NP	O
minutes	minute	NNS	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
50s	50	NNS	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
input	input	NN	B-NP	O
was	be	VBD	B-VP	O
elicited	elicit	VBN	I-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
cardiology	cardiology	NN	I-NP	O
consult	consult	NN	I-NP	O
service	service	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
thought	think	VBD	B-VP	O
that	that	IN	B-SBAR	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
were	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
diltiazem	diltiazem	NN	I-NP	O
drip	drip	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
given	give	VBN	B-NP	O
concern	concern	NN	I-NP	O
for	for	IN	B-PP	O
a	a	DT	B-NP	O
tachy-brady	tachy-brady	JJ	I-NP	O
syndrome	syndrome	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
possibility	possibility	NN	I-NP	O
of	of	IN	B-PP	O
an	an	DT	B-NP	O
implantable	implantable	JJ	I-NP	O
cardiac	cardiac	JJ	I-NP	O
pacemaker	pacemaker	NN	I-NP	O
was	be	VBD	B-VP	O
discussed	discuss	VBN	I-VP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
have	have	VB	I-VP	O
any	any	DT	B-NP	O
recurrence	recurrence	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
junctional	junctional	JJ	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

A	A	DT	B-NP	O
TTE	TTE	NN	I-NP	B-DNA
was	be	VBD	B-VP	O
obtained	obtain	VBN	I-VP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
an	an	DT	B-NP	O
ejection	ejection	NN	I-NP	O
fraction	fraction	NN	I-NP	O
of	of	IN	B-PP	O
60	60	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
trace	trace	NN	B-NP	B-protein
MR	MR	NN	I-NP	I-protein
and	and	CC	O	O
moderate	moderate	JJ	B-NP	O
TR	TR	NN	I-NP	O
,	,	,	O	O
left	left	JJ	B-NP	O
and	and	CC	I-NP	O
right	right	JJ	I-NP	O
atrial	atrial	JJ	I-NP	O
enlargement	enlargement	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
normal	normal	JJ	B-NP	O
left	left	JJ	I-NP	O
and	and	CC	I-NP	O
right	right	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

Once	Once	RB	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
again	again	RB	I-VP	O
taking	take	VBG	I-VP	O
p.o.	p.o.	FW	B-NP	O
medications	medication	NNS	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
diltiazem	diltiazem	NN	I-NP	O
drip	drip	NN	I-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
p.o.	p.o.	FW	B-NP	O
diltiazem	diltiazem	NN	I-NP	O
.	.	.	O	O

For	For	IN	B-PP	O
the	the	DT	B-NP	O
next	next	JJ	I-NP	O
several	several	JJ	I-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
several	several	JJ	B-NP	O
episodes	episode	NNS	I-NP	O
each	each	DT	B-NP	O
night	night	NN	I-NP	O
of	of	IN	B-PP	O
3	3	CD	B-NP	O
to	to	TO	I-NP	O
5	5	CD	I-NP	O
beat	beat	NN	I-NP	O
runs	run	NNS	I-NP	O
of	of	IN	B-PP	O
NSVT	NSVT	NN	B-NP	B-protein
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
on	on	IN	B-PP	O
the	the	DT	B-NP	O
three	three	CD	I-NP	O
days	day	NNS	I-NP	O
prior	prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
events	event	NNS	I-NP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
60s	60	NNS	I-NP	B-DNA
to	to	TO	B-PP	I-DNA
80s	80	NNS	B-NP	I-DNA
,	,	,	O	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
running	run	VBG	B-VP	O
from	from	IN	B-PP	O
90-100/50	90-100/50	CD	B-NP	O
-60	-60	CD	I-NP	O
.	.	.	O	O

Shortly	Shortly	RB	B-ADVP	O
before	before	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
also	also	RB	B-ADVP	O
developed	develop	VBD	B-VP	O
episodic	episodic	JJ	B-NP	O
shortness	shortness	NN	I-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
was	be	VBD	B-VP	O
attributed	attribute	VBN	I-VP	O
to	to	TO	B-PP	O
mild	mild	JJ	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
responded	respond	VBD	B-VP	O
well	well	RB	B-ADVP	O
to	to	TO	B-PP	O
boluses	bolus	NNS	B-NP	O
of	of	IN	B-PP	O
IV	IV	CD	B-NP	O
Lasix	Lasix	NNP	I-NP	O
.	.	.	O	O

As	As	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
Aldactone	Aldactone	NN	B-NP	O
with	with	IN	B-PP	O
effective	effective	JJ	B-NP	O
gentle	gentle	JJ	I-NP	O
diuresis	diuresis	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
plan	plan	NN	I-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
to	to	TO	B-VP	O
follow	follow	VB	I-VP	O
her	her	PRP$	B-NP	O
volume	volume	NN	I-NP	O
status	status	NN	I-NP	O
carefully	carefully	RB	B-ADVP	O
and	and	CC	O	O
to	to	TO	B-VP	O
adjust	adjust	VB	I-VP	O
her	her	PRP$	B-NP	O
diuretic	diuretic	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
her	her	PRP$	B-NP	O
volume	volume	NN	I-NP	O
status	status	NN	I-NP	O
with	with	IN	B-PP	O
continued	continue	VBN	B-NP	O
improvement	improvement	NN	I-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
hepatic	hepatic	JJ	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Endocrine	Endocrine	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
diabetes	diabetes	NN	B-NP	O
mellitus	mellitus	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
her	her	PRP$	B-NP	O
metformin	metformin	NN	I-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
an	an	DT	B-NP	O
elevated	elevated	JJ	I-NP	O
creatinine	creatinine	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
lispro	lispro	NN	I-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	O
.	.	.	O	O

Given	Give	VBN	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
n.p.o.	n.p.o.	NN	B-NP	O
for	for	IN	B-PP	O
several	several	JJ	B-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
given	give	VBN	I-VP	O
any	any	DT	B-NP	O
insulin	insulin	NN	I-NP	B-protein
and	and	CC	O	O
her	her	PRP$	B-NP	O
blood	blood	NN	I-NP	O
sugars	sugar	NNS	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
low	low	JJ	I-NP	O
100s	100	NNS	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
she	she	PRP	B-NP	O
again	again	RB	B-ADVP	O
started	start	VBD	B-VP	O
taking	take	VBG	I-VP	O
p.o.	p.o.	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
restarted	restart	VBN	I-VP	O
on	on	IN	B-PP	O
a	a	DT	B-NP	O
sliding	slide	VBG	I-NP	O
scale	scale	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
maintained	maintain	VBD	B-VP	O
excellent	excellent	JJ	B-NP	O
blood	blood	NN	I-NP	O
sugar	sugar	NN	I-NP	O
control	control	NN	I-NP	O
between	between	IN	B-PP	O
100	100	CD	B-NP	B-DNA
and	and	CC	I-NP	I-DNA
150	150	CD	I-NP	I-DNA
.	.	.	O	O

A	A	DT	B-NP	O
hemoglobin	hemoglobin	NN	I-NP	B-protein
A1c	A1c	NN	I-NP	O
obtained	obtain	VBN	B-VP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
was	be	VBD	B-VP	O
also	also	RB	B-ADVP	O
within	within	IN	B-PP	O
normal	normal	JJ	B-NP	O
limits	limit	NNS	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
left	left	JJ	I-NP	O
toe	toe	NN	I-NP	O
ulcer	ulcer	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
orthopedic	orthopedic	JJ	B-NP	O
surgeries	surgery	NNS	I-NP	O
and	and	CC	O	O
outpatient	outpatient	NN	B-NP	O
totally	totally	RB	B-ADVP	O
before	before	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Heme	Heme	NN	B-NP	B-protein
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
an	an	DT	B-NP	O
INR	INR	NN	I-NP	B-protein
of	of	IN	B-PP	O
2.6	2.6	CD	B-NP	O
on	on	IN	B-PP	O
admission	admission	NN	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
cirrhosis	cirrhosis	NN	B-NP	O
and	and	CC	O	O
poor	poor	JJ	B-NP	O
nutrition	nutrition	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
vitamin	vitamin	NN	B-NP	O
K	K	NN	I-NP	O
subcu	subcu	NN	I-NP	O
n.p.o.	n.p.o.	NN	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	IN	B-PP	O
,	,	,	O	O
despite	despite	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
not	not	RB	O	O
on	on	IN	B-PP	O
Coumadin	Coumadin	NN	B-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
poor	poor	JJ	B-NP	O
med	med	JJ	I-NP	O
compliance	compliance	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
home	home	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
only	only	RB	B-ADVP	O
on	on	IN	B-PP	O
aspirin	aspirin	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
also	also	RB	I-VP	O
discontinue	discontinue	VB	I-VP	O
during	during	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
continued	continue	VBN	B-NP	O
guaiac	guaiac	JJ	I-NP	O
positive	positive	JJ	I-NP	O
stool	stool	NN	I-NP	O
.	.	.	O	O

Nevertheless	Nevertheless	RB	B-ADVP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
hematocrit	hematocrit	NN	I-NP	O
remained	remain	VBD	B-VP	O
stable	stable	JJ	B-ADJP	O
throughout	throughout	IN	B-PP	O
her	her	PRP$	B-NP	O
admission	admission	NN	I-NP	O
and	and	CC	O	O
she	she	PRP	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
require	require	VB	I-VP	O
any	any	DT	B-NP	O
transfusions	transfusion	NNS	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
DVT	DVT	NN	B-NP	O
prophylaxis	prophylaxis	NN	I-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
kept	keep	VBN	I-VP	O
on	on	IN	B-PP	O
Pneumo	Pneumo	NNP	B-NP	O
boots	boot	NNS	I-NP	O
throughout	throughout	IN	B-PP	O
the	the	DT	B-NP	O
admission	admission	NN	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
one	one	CD	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
noted	note	VBN	I-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
left	leave	VBN	I-VP	O
upper	upper	JJ	B-NP	O
extremity	extremity	NN	I-NP	O
swelling	swell	VBG	B-VP	O
greater	great	JJR	B-ADJP	O
than	than	IN	B-PP	O
the	the	DT	B-NP	O
right	right	JJ	I-NP	O
upper	upper	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
an	an	DT	B-NP	O
ultrasound	ultrasound	NN	I-NP	O
was	be	VBD	B-VP	O
negative	negative	JJ	B-ADJP	O
for	for	IN	B-PP	O
DVT	DVT	NN	B-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	IN	B-PP	O
,	,	,	O	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
INR	INR	NN	I-NP	B-protein
was	be	VBD	B-VP	O
improving	improve	VBG	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-PP	O
improved	improve	VBN	B-NP	O
nutrition	nutrition	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
without	without	IN	B-PP	O
any	any	DT	B-NP	O
anticoagulation	anticoagulation	NN	I-NP	O
at	at	IN	B-PP	O
present	present	NN	B-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
this	this	DT	B-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
further	further	RBR	B-ADJP	O
reevaluated	reevaluate	VBN	I-ADJP	O
as	as	IN	B-PP	O
an	an	DT	B-NP	O
outpatient	outpatient	NN	I-NP	O
by	by	IN	B-PP	O
her	her	PRP$	B-NP	O
cardiologist	cardiologist	NN	I-NP	O
and	and	CC	I-NP	O
oncologist	oncologist	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

FEN	FEN	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	I-VP	O
rehydrated	rehydrate	VBN	I-VP	O
with	with	IN	B-PP	O
normal	normal	JJ	B-NP	O
saline	saline	NN	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
this	this	DT	B-NP	O
was	be	VBD	B-VP	O
changed	change	VBN	I-VP	O
to	to	TO	B-PP	O
D5W	D5W	NN	B-NP	B-protein
plus	plus	CC	O	O
3	3	CD	B-NP	O
amps	amp	NNS	I-NP	O
of	of	IN	B-PP	O
bicarb	bicarb	NN	B-NP	O
since	since	IN	B-SBAR	O
she	she	PRP	B-NP	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
bicarb	bicarb	NN	I-NP	O
gap	gap	NN	I-NP	O
.	.	.	O	O

Once	Once	RB	O	O
this	this	DT	B-NP	O
gap	gap	NN	I-NP	B-protein
was	be	VBD	B-VP	O
closed	close	VBN	I-VP	O
,	,	,	O	O
she	she	PRP	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
gentle	gentle	JJ	B-NP	O
normal	normal	JJ	I-NP	O
saline	saline	NN	I-NP	O
as	as	IN	B-PP	O
maintenance	maintenance	NN	B-NP	O
fluids	fluid	NNS	I-NP	O
.	.	.	O	O

Once	Once	RB	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
started	start	VBD	B-VP	O
taking	take	VBG	I-VP	O
significant	significant	JJ	B-NP	O
p.o.	p.o.	NN	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
IV	IV	CD	I-NP	O
fluids	fluid	NNS	I-NP	O
were	be	VBD	B-VP	O
discontinued	discontinue	VBN	I-VP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
electrolytes	electrolyte	NNS	I-NP	O
were	be	VBD	B-VP	O
also	also	RB	I-VP	O
repleted	replete	VBN	I-VP	O
as	as	IN	B-PP	O
necessary	necessary	JJ	B-ADJP	O
.	.	.	O	O

Plan	Plan	NN	B-NP	O
on	on	IN	B-PP	O
discharge	discharge	NN	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
to	to	TO	B-VP	O
continue	continue	VB	I-VP	O
following	follow	VBG	I-VP	O
her	her	PRP$	B-NP	O
electrolytes	electrolyte	NNS	I-NP	O
closely	closely	RB	B-ADVP	O
to	to	TO	B-VP	O
prevent	prevent	VB	I-VP	O
further	further	JJ	B-NP	O
exacerbation	exacerbation	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
cardiac	cardiac	JJ	I-NP	O
arrhythmias	arrhythmia	NNS	I-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

Pain	Pain	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
oxycodone	oxycodone	NN	B-NP	O
p.o.	p.o.	NN	I-NP	O
and	and	CC	O	O
morphine	morphine	NN	B-NP	O
IV	IV	CD	I-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
previously	previously	RB	B-ADVP	O
on	on	IN	B-PP	O
Vioxx	Vioxx	NN	B-NP	O
at	at	IN	B-PP	O
home	home	NN	B-NP	O
for	for	IN	B-PP	O
orthopedic	orthopedic	JJ	B-NP	O
pain	pain	NN	I-NP	O
related	relate	VBN	B-VP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
diabetes	diabete	NNS	I-NP	O
,	,	,	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
given	give	VBN	B-PP	O
recent	recent	JJ	B-NP	O
data	datum	NNS	I-NP	O
suggesting	suggest	VBG	B-VP	O
possible	possible	JJ	B-NP	O
cardiotoxic	cardiotoxic	JJ	I-NP	O
effects	effect	NNS	I-NP	O
of	of	IN	B-PP	O
Vioxx	Vioxx	NNP	B-NP	O
,	,	,	O	O
this	this	DT	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discontinued	discontinue	VBN	I-VP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
with	with	IN	B-PP	O
oxycodone	oxycodone	NN	B-NP	O
p.r.n.	p.r.n.	NN	I-NP	O
for	for	IN	B-PP	O
pain	pain	NN	B-NP	O
.	.	.	O	O

8	8	CD	B-NP	O
.	.	.	O	O

Onc	Onc	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
Xeloda	Xeloda	NN	I-NP	O
is	be	VBZ	B-VP	O
currently	currently	RB	B-ADVP	O
on	on	IN	B-PP	O
hold	hold	NN	B-NP	O
since	since	IN	B-SBAR	O
many	many	JJ	B-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
symptoms	symptom	NNS	I-NP	O
leading	lead	VBG	B-VP	O
up	up	RB	B-ADVP	O
to	to	TO	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
were	be	VBD	B-VP	O
likely	likely	RB	B-ADJP	O
secondary	secondary	JJ	I-ADJP	O
to	to	TO	B-PP	O
chemo	chemo	NN	B-NP	O
toxicity	toxicity	NN	I-NP	O
.	.	.	O	O

As	As	IN	B-SBAR	O
noted	note	VBN	B-VP	O
above	above	RB	B-ADVP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
other	other	JJ	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
chemo	chemo	NN	B-NP	O
toxicity	toxicity	NN	I-NP	O
as	as	RB	B-ADVP	O
well	well	RB	I-ADVP	O
,	,	,	O	O
including	include	VBG	B-PP	O
significantly	significantly	RB	B-ADVP	O
dried	dry	VBD	B-VP	O
skin	skin	NN	B-NP	O
on	on	IN	B-PP	O
her	her	PRP$	B-NP	O
hands	hand	NNS	I-NP	O
and	and	CC	I-NP	O
feet	foot	NNS	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
outpatient	outpatient	NN	I-NP	O
oncologist	oncologist	NN	I-NP	O
,	,	,	O	O
Dr.	Dr.	NNP	B-NP	O
Willard	Willard	NNP	I-NP	O
Brixius	Brixius	NNP	I-NP	O
,	,	,	O	O
followed	follow	VBD	B-VP	O
her	her	PRP	B-NP	O
closely	closely	RB	B-ADVP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
admission	admission	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
regarding	regard	VBG	B-VP	O
possible	possible	JJ	B-NP	O
changes	change	NNS	I-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
chemotherapy	chemotherapy	NN	I-NP	O
regimen	regimen	NN	I-NP	O
.	.	.	O	O

9	9	CD	B-NP	O
.	.	.	O	O

Disposition	Disposition	NN	B-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
seen	see	VBN	I-VP	O
by	by	IN	B-PP	O
the	the	DT	B-NP	O
physical	physical	JJ	I-NP	O
therapy	therapy	NN	I-NP	O
service	service	NN	I-NP	O
shortly	shortly	RB	B-ADVP	O
before	before	IN	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
they	they	PRP	B-NP	O
noted	note	VBD	B-VP	O
that	that	IN	B-SBAR	O
she	she	PRP	B-NP	O
displayed	display	VBD	B-VP	O
difficulty	difficulty	NN	B-NP	O
even	even	RB	B-ADVP	O
moving	move	VBG	B-VP	O
from	from	IN	B-PP	O
the	the	DT	B-NP	O
bed	bed	NN	I-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
chair	chair	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
is	be	VBZ	B-VP	O
significantly	significantly	RB	B-ADVP	O
below	below	IN	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
of	of	IN	B-PP	O
being	be	VBG	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
ambulate	ambulate	VB	I-VP	O
independently	independently	RB	B-ADVP	O
.	.	.	O	O

As	As	IN	B-PP	O
a	a	DT	B-NP	O
result	result	NN	I-NP	O
,	,	,	O	O
after	after	IN	B-SBAR	O
extensive	extensive	JJ	B-NP	O
discussions	discussion	NNS	I-NP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
family	family	NN	I-NP	O
,	,	,	O	O
it	it	PRP	B-NP	O
was	be	VBD	B-VP	O
decided	decide	VBN	I-VP	O
that	that	IN	B-SBAR	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
best	well	RBS	I-VP	O
served	serve	VBN	I-VP	O
by	by	IN	B-PP	O
going	go	VBG	B-VP	O
to	to	TO	B-PP	O
a	a	DT	B-NP	O
rehab	rehab	NN	I-NP	O
facility	facility	NN	I-NP	O
for	for	IN	B-PP	O
continued	continue	VBN	B-NP	O
closed	closed	JJ	I-NP	O
supervision	supervision	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
medical	medical	JJ	I-NP	O
problems	problem	NNS	I-NP	O
,	,	,	O	O
supervised	supervised	JJ	B-NP	O
administration	administration	NN	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
medication	medication	NN	I-NP	O
regimen	regimen	NN	I-NP	O
,	,	,	O	O
continued	continue	VBD	B-VP	O
strength	strength	NN	B-NP	O
training	training	NN	I-NP	O
and	and	CC	I-NP	O
conditioning	conditioning	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
also	also	RB	B-ADVP	O
continued	continue	VBD	B-VP	O
nutrition	nutrition	NN	B-NP	O
.	.	.	O	O

Once	Once	RB	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
is	be	VBZ	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
less	less	RBR	B-ADJP	O
dependent	dependent	JJ	I-ADJP	O
on	on	IN	B-PP	O
outside	outside	JJ	B-NP	O
assistance	assistance	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
can	can	MD	B-VP	O
be	be	VB	I-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
with	with	IN	B-PP	O
either	either	CC	O	O
a	a	DT	B-NP	O
home	home	NN	I-NP	O
health	health	NN	I-NP	O
aide	aide	NN	I-NP	O
or	or	CC	O	O
visiting	visit	VBG	B-VP	O
nurse	nurse	NN	B-NP	O
for	for	IN	B-PP	O
continued	continued	JJ	B-NP	O
rehabilitation	rehabilitation	NN	I-NP	O
.	.	.	O	O

Of	Of	IN	B-PP	O
note	note	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
code	code	NN	I-NP	O
status	status	NN	I-NP	O
was	be	VBD	B-VP	O
established	establish	VBN	I-VP	O
by	by	IN	B-PP	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
oncologist	oncologist	NN	I-NP	O
as	as	IN	B-PP	O
DNR/DNI	DNR/DNI	NN	B-NP	B-protein
.	.	.	O	O

This	This	DT	B-NP	O
was	be	VBD	B-VP	O
confirmed	confirm	VBN	I-VP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
during	during	IN	B-PP	O
this	this	DT	B-NP	O
hospitalization	hospitalization	NN	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAMINATION	EXAMINATION	NN	I-NP	O
ON	ON	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Vital	Vital	JJ	B-NP	O
signs	sign	NNS	I-NP	O
:	:	:	O	O
Temperature	Temperature	NN	B-NP	B-protein
98.3	98.3	CD	I-NP	I-protein
,	,	,	O	O
pulse	pulse	NN	B-NP	O
80	80	CD	I-NP	O
,	,	,	O	O
blood	blood	NN	B-NP	O
pressure	pressure	NN	I-NP	O
104/64	104/64	CD	I-NP	O
,	,	,	O	O
respiratory	respiratory	JJ	B-NP	O
rate	rate	NN	I-NP	O
20	20	CD	I-NP	O
,	,	,	O	O
O2	O2	NN	B-NP	O
sat	sit	VBD	B-VP	O
99	99	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

General	General	NNP	B-NP	O
:	:	:	O	O
Alert	Alert	NNP	B-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
acute	acute	JJ	I-NP	O
distress	distress	NN	I-NP	O
,	,	,	O	O
icteric	icteric	JJ	B-NP	O
sclerae	sclerae	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
slightly	slightly	RB	B-VP	O
jaundiced	jaundice	VBN	I-VP	O
.	.	.	O	O

Respiratory	Respiratory	JJ	B-ADJP	O
:	:	:	O	O
CTAB	CTAB	NN	B-NP	B-protein
except	except	IN	B-PP	O
for	for	IN	B-PP	O
few	few	JJ	B-NP	O
crackles	crackle	NNS	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
bases	base	NNS	I-NP	O
bilaterally	bilaterally	RB	B-ADVP	O
.	.	.	O	O

CV	CV	NN	B-NP	O
:	:	:	O	O
Irregularly	Irregularly	RB	B-NP	O
irregular	irregular	JJ	I-NP	O
S1	S1	NN	I-NP	O
,	,	,	O	O
S2	S2	NN	B-NP	B-protein
,	,	,	O	O
1/6	1/6	CD	B-NP	O
SM	SM	NN	I-NP	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
left	left	JJ	I-NP	O
upper	upper	JJ	I-NP	O
sternal	sternal	JJ	I-NP	O
border	border	NN	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
rubs/gallops	rubs/gallop	NNS	I-NP	O
.	.	.	O	O

Abdomen	Abdoman	NNS	B-NP	O
:	:	:	O	O
Soft	Soft	NNP	B-NP	O
,	,	,	O	O
distended	distend	VBD	B-VP	O
-LRB-	-LRB-	NNP	B-NP	O
decreased	decrease	VBD	B-VP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
mildly	mildly	RB	B-NP	O
tender	tender	NN	I-NP	O
to	to	TO	B-PP	O
palpation	palpation	NN	B-NP	O
diffusely	diffusely	RB	B-ADVP	O
,	,	,	O	O
normoactive	normoactive	JJ	B-NP	O
bowel	bowel	NN	I-NP	O
sounds	sound	NNS	I-NP	O
.	.	.	O	O

Extremities	Extremity	NNS	B-NP	O
:	:	:	O	O
Warm/well	Warm/well	NNP	B-NP	O
perfused	perfuse	VBD	B-VP	O
,	,	,	O	O
nontender	nontender	JJ	B-ADJP	O
,	,	,	O	O
1	1	CD	B-NP	O
to	to	TO	I-NP	O
2	2	CD	I-NP	O
+	+	SYM	I-NP	O
pedal	pedal	JJ	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
1	1	CD	B-NP	O
to	to	TO	I-NP	O
2	2	CD	I-NP	O
+	+	SYM	I-NP	O
left	left	JJ	I-NP	O
upper	upper	JJ	I-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
,	,	,	O	O
significantly	significantly	RB	B-VP	O
dry/cracked	dry/cracke	VBD	I-VP	O
skin	skin	NN	B-NP	O
on	on	IN	B-PP	O
hands	hand	NNS	B-NP	O
and	and	CC	I-NP	O
feet	foot	NNS	I-NP	O
.	.	.	O	O

LABORATORY	LABORATORY	NN	B-NP	O
VALUES	VALUES	VBZ	B-VP	O
ON	ON	NN	B-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
:	:	:	O	O
Sodium	Sodium	NN	B-NP	O
137	137	CD	I-NP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
4.3	4.3	CD	I-NP	O
,	,	,	O	O
bicarb	bicarb	NN	B-NP	O
26	26	CD	I-NP	O
,	,	,	O	O
creatinine	creatinine	NN	B-NP	O
1.0	1.0	CD	I-NP	O
,	,	,	O	O
glucose	glucose	NN	B-NP	B-protein
61	61	CD	I-NP	I-protein
,	,	,	O	O
calcium	calcium	NN	B-NP	O
7.8	7.8	CD	I-NP	O
,	,	,	O	O
magnesium	magnesium	NN	B-NP	O
2.2	2.2	CD	I-NP	O
,	,	,	O	O
WBC	WBC	NNP	B-NP	O
15.1	15.1	CD	I-NP	O
with	with	IN	B-PP	O
87	87	CD	B-NP	O
%	%	NN	I-NP	O
polys	poly	NNS	I-NP	O
,	,	,	O	O
HCT	HCT	NN	B-NP	B-cell_line
36.8	36.8	CD	I-NP	I-cell_line
,	,	,	O	O
platelets	platelet	NNS	B-NP	B-cell_type
101	101	CD	I-NP	O
,	,	,	I-NP	O
000	000	CD	I-NP	O
,	,	,	O	O
INR	INR	NN	B-NP	B-protein
1.6	1.6	CD	I-NP	I-protein
,	,	,	O	O
ALT	ALT	NN	B-NP	B-DNA
18	18	CD	I-NP	I-DNA
,	,	,	O	O
AST	AST	NN	B-NP	O
46	46	CD	I-NP	O
,	,	,	O	O
alk	alk	NN	B-NP	O
phos	pho	NNS	I-NP	O
103	103	CD	B-NP	O
,	,	,	O	O
T.	T.	NNP	B-NP	B-protein
bili	bili	NNP	I-NP	I-protein
16.0	16.0	CD	I-NP	I-protein
,	,	,	O	O
total	total	JJ	B-NP	O
protein	protein	NN	I-NP	O
5.8	5.8	CD	I-NP	O
,	,	,	O	O
albumin	albumin	NN	B-NP	O
1.9	1.9	CD	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Lispro	Lispro	NN	B-NP	O
sliding	slide	VBG	B-VP	O
scale	scale	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
less	less	JJR	B-ADJP	O
than	than	IN	B-PP	O
135	135	CD	B-NP	O
,	,	,	O	O
give	give	VB	B-VP	O
0	0	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
125	125	CD	B-NP	O
to	to	TO	B-PP	O
150	150	CD	B-NP	O
,	,	,	O	O
then	then	RB	O	O
give	give	VB	B-VP	O
2	2	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
151	151	CD	B-NP	O
to	to	TO	B-PP	O
200	200	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
3	3	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
201	201	CD	B-NP	O
to	to	TO	B-PP	O
250	250	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
4	4	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
251	251	CD	B-NP	O
to	to	TO	B-PP	O
300	300	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
6	6	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
301	301	CD	B-NP	O
to	to	TO	B-PP	O
350	350	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
8	8	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
;	;	:	O	O
if	if	IN	B-SBAR	O
blood	blood	NN	B-NP	O
sugar	sugar	NN	I-NP	O
is	be	VBZ	B-VP	O
351	351	CD	B-NP	O
to	to	TO	B-PP	O
400	400	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
give	give	VB	B-VP	O
10	10	CD	B-NP	O
units	unit	NNS	I-NP	O
subcutaneously	subcutaneously	RB	B-ADVP	O
-RRB-	-RRB-	NN	B-NP	O
,	,	,	O	O
multivitamin	multivitamin	NN	B-NP	O
one	one	CD	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
diltiazem	diltiazem	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
t.i.d.	t.i.d.	NN	I-NP	O
,	,	,	O	O
Aldactone	Aldactone	NNP	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
q.d.	q.d.	NN	I-NP	O
,	,	,	O	O
oxycodone	oxycodone	NN	B-NP	O
5	5	CD	I-NP	O
to	to	TO	I-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
4h	4h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
pain	pain	NN	B-NP	O
,	,	,	O	O
trazodone	trazodone	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.h.s.	q.h.s.	FW	I-NP	O
p.r.n.	p.r.n.	FW	I-NP	O
insomnia	insomnia	NN	I-NP	O
,	,	,	O	O
Compazine	Compazine	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.	q.	NN	I-NP	O
6h	6h	NN	I-NP	O
.	.	.	O	O

p.r.n.	p.r.n.	LS	B-LST	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
vitamin	vitamin	NN	B-NP	O
K	K	NN	I-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
q.d.	q.d.	FW	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	I-VP	O
rehab	rehab	VB	I-VP	O
in	in	IN	B-PP	O
stable	stable	JJ	B-NP	O
condition	condition	NN	I-NP	O
.	.	.	O	O

PHYSICIAN	PHYSICIAN	NN	B-NP	O
FOLLOW-UP	FOLLOW-UP	NN	I-NP	O
PLANS	PLANS	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
be	be	VB	I-VP	O
discharged	discharge	VBN	I-VP	O
to	to	TO	B-PP	O
rehabilitation	rehabilitation	NN	B-NP	O
facility	facility	NN	I-NP	O
,	,	,	O	O
where	where	WRB	B-ADVP	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
supportive	supportive	JJ	B-NP	O
care	care	NN	I-NP	O
for	for	IN	B-PP	O
ongoing	ongoing	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
her	her	PRP$	B-NP	O
enteritis	enteritis	NN	I-NP	O
and	and	CC	I-NP	O
hepatic	hepatic	JJ	I-NP	O
failure	failure	NN	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
also	also	RB	I-VP	O
receive	receive	VB	I-VP	O
physical	physical	JJ	B-NP	O
therapy	therapy	NN	I-NP	O
and	and	CC	I-NP	O
nutrition	nutrition	NN	I-NP	O
to	to	TO	B-VP	O
help	help	VB	I-VP	O
her	her	PRP$	B-NP	O
return	return	NN	I-NP	O
to	to	TO	B-PP	O
her	her	PRP$	B-NP	O
baseline	baseline	NN	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

Prior	Prior	RB	B-ADVP	O
to	to	TO	B-VP	O
discharge	discharge	VB	I-VP	O
from	from	IN	B-PP	O
rehab	rehab	NN	B-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
medication	medication	NN	I-NP	O
regimen	regimen	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
simplified	simplify	VBN	I-VP	O
as	as	RB	B-ADVP	O
much	much	RB	I-ADVP	O
as	as	IN	B-PP	O
possible	possible	JJ	B-ADJP	O
to	to	TO	B-VP	O
prevent	prevent	VB	I-VP	O
future	future	JJ	B-NP	O
confusion	confusion	NN	I-NP	O
over	over	IN	B-PP	O
her	her	PRP$	B-NP	O
medications	medication	NNS	I-NP	O
,	,	,	O	O
as	as	IN	B-SBAR	O
has	have	VBZ	B-VP	O
happened	happen	VBN	I-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
past	past	NN	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
discharge	discharge	NN	B-NP	O
from	from	IN	B-PP	O
rehab	rehab	NN	B-NP	O
,	,	,	O	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
should	should	MD	B-VP	O
be	be	VB	I-VP	O
sent	send	VBN	I-VP	O
home	home	NN	B-ADVP	O
with	with	IN	B-PP	O
either	either	CC	O	O
a	a	DT	B-NP	O
visiting	visit	VBG	I-NP	O
nurse	nurse	NN	I-NP	O
or	or	CC	I-NP	O
home	home	NN	I-NP	O
health	health	NN	I-NP	O
aide	aide	NN	I-NP	O
,	,	,	O	O
as	as	IN	B-SBAR	O
insurance	insurance	NN	B-NP	O
permits	permit	NNS	I-NP	O
.	.	.	O	O

At	At	IN	B-PP	O
that	that	DT	B-NP	O
point	point	NN	I-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Snellbaker	Snellbaker	NNP	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
physician	physician	NN	I-NP	O
;	;	:	O	O
Dr.	Dr.	NNP	B-NP	O
Fushimi	Fushimi	NNP	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
oncologist	oncologist	NN	I-NP	O
;	;	:	O	O
and	and	CC	O	O
Dr.	Dr.	NNP	B-NP	O
Khalili	Khalili	NNP	I-NP	O
,	,	,	O	O
her	her	PRP$	B-NP	O
outpatient	outpatient	NN	I-NP	O
cardiologist	cardiologist	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
5-4163960	5-4163960	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
DHILLON	DHILLON	NN	B-NP	O
,	,	,	O	O
TOBY	TOBY	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
PANKAU	PANKAU	NNP	B-NP	O
,	,	,	O	O
WILFORD	WILFORD	NNP	B-NP	O
EDWIN	EDWIN	NNP	I-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
5564979	5564979	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
3/1/04	3/1/04	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
3/1/04	3/1/04	CD	B-NP	O

